TY - JOUR T1 - Phe2vec: Automated Disease Phenotyping based on Unsupervised Embeddings from Electronic Health Records JF - medRxiv DO - 10.1101/2020.11.14.20231894 SP - 2020.11.14.20231894 AU - Jessica K. De Freitas AU - Kipp W. Johnson AU - Eddye Golden AU - Girish N. Nadkarni AU - Joel T. Dudley AU - Erwin P. Bottinger AU - Benjamin S. Glicksberg AU - Riccardo Miotto Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/01/30/2020.11.14.20231894.abstract N2 - Objective We introduce Phe2vec, an automated framework for disease phenotyping from electronic health records (EHRs) based on unsupervised learning. We assess its effectiveness against standard rule-based algorithms from the Phenotype KnowledgeBase (PheKB).Materials and Methods Phe2vec is based on pre-computing embeddings of medical concepts and patients’ longitudinal clinical history. Disease phenotypes are then derived from a seed concept and its neighbors in the embedding space. Patients are similarly linked to a disease if their embedded representation is close to the phenotype. We evaluated Phe2vec using 49,234 medical concepts from structured EHRs and clinical notes from 1,908,741 patients in the Mount Sinai Health System. We assessed performance on ten diverse diseases having a PheKB algorithm, and one disease without, namely Lyme disease.Results Phe2vec phenotypes derived using Word2vec, GloVe, and Fasttext embeddings led to promising performance in disease definition and patient cohort identification with respect to phenotypes and cohorts obtained by PheKB. When comparing head-to-head Phe2vec and PheKB disease patient cohorts using chart review, Phe2vec performed on par or better in nine out of ten diseases in terms of positive predictive values. Additionally, Phe2vec effectively identified phenotype definition and patient cohort for Lyme disease, a condition not covered in PheKB.Discussion Phe2vec offers a solution to improve time-consuming phenotyping pipelines. Differently from other automated approaches in the literature, it is unsupervised, can easily scale to any disease and was validated against widely adopted expert-based standards.Conclusion Phe2vec aims to optimize clinical informatics research by augmenting current frameworks to characterize patients by condition and derive reliable disease cohorts.Competing Interest StatementThe authors have declared no competing interest.Funding StatementSupport from the Hasso Plattner Foundation and the Alzheimer's Drug Discovery Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved under IRB-19-02369 by the Program for the Protection of Human Subjects at the Icahn School of Medicine at Mount Sinai.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesn/a ER -